| 产品描述: | ARN19702是一种口服活性、可逆的N-酰乙醇酰胺酰胺酶(N-Acylethanolamine acid amidase, NAAA)抑制剂(在人NAAA上的IC50为230 nM),对小鼠多发性硬化具有显著的保护作用 |
| 靶点: |
NAAA:0.23 μM |
| 体外研究: |
ARN19702 is a selective, orally active, reversible and brain-penetrant N-acylethanolamine acid amidase (NAAA), by a non-covalent mechanism |
| 体内研究: |
ARN-19702 attenuates the spontaneous nocifensive response elicited and the hypersensitivity in male mouse model of acute and neuropathic pain, also reduces nociception associated with paclitaxel-induced neuropathy without development of subacute antinociceptive tolerance in male rat model of acute and neuropathic pain |
| 细胞实验: |
Cell lines: HEK293 cells Concentrations: -- Incubation Time: 2 h Method: Lysosomal extracts of hNAAA-overexpressing HEK293 cells are incubated with vehicle (2% DMSO), ARN-19702, for 2 h before addition of activity-based NAAA probe |
| 动物实验: |
Animal Models: mouse and rat models of acute and neuropathic pain Dosages: 3-10 mg/kg for male rats; 0.1-30 mg/kg for male mice Administration: p.o. |
| 参考文献: |
1. Migliore M Dr, et al. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis. Angew Chem Int Ed Engl. 2016 Sep 5;55(37):11193-11197. 2. Fotio Y, et al. Antinociceptive Profile of ARN19702, (2-Ethylsulfonylphenyl)-[(2S)-4-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazin-1-yl]methanone, a Novel Orally Active N-Acylethanolamine Acid Amidase Inhibitor, in Animal Models. J Pharmacol Exp Ther. 2021 Aug;378(2):70-76. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.234 ml |
11.172 ml |
22.344 ml |
| 5 mM |
0.447 ml |
2.234 ml |
4.469 ml |
| 10 mM |
0.223 ml |
1.117 ml |
2.234 ml |
| 50 mM |
0.045 ml |
0.223 ml |
0.447 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |